BioCentury on BioBusiness,
Tools & Techniques
Nuvelo's stealth target
Monday, June 18, 2007
Ever since Nuvelo Inc. was formed through the merger of Hyseq Pharmaceuticals Inc. and Variagenics Inc. in 2003, the company's clinical focus has been on compounds in-licensed from third parties. Although it's been relatively silent about the internal discovery engine, NUVO maintains it has been productive. Earlier this month, the company unveiled the first cancer antibody from its internal research.
NUVO (San Carlos, Calif.) published in the British Journal of Haematology the identification of NTB-A, a cell surface protein in the signaling lymphocytic activation molecule (SLAM) family. According to the company, NTB-A is overexpressed on malignant lymphoid cells, including B cells from patients with leukemia
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]